Xuri IL-2 is a dedicated cell therapy ancillary product for the ex vivo cultivation of T-lymphocytes. Xuri IL-2s defined level of biological activity removes the need for revalidation of each lot and strongly improves reproducibility, thereby minimizing process development time and improving scale out capacity.

Xuri IL-2 features low endotoxin levels (<0.025 EU/g), is produced under a GMP license certified and regularly audited, quality controlled under ISO9001:2008 and in accordance with the International Conference on Harmonization (ICH) guideline. Xuri IL-2 is supplied with comprehensive instructions for straightforward expansion in static culture and with the Xuri Cell Expansion Systems W5 and W25.

Also now available is IL-2 for preclinical use, a cost efficient alternative for the cultivation of T-lymphocytes in proof-of-principle and basic research experiments. The close equivalence between IL-2 and Xuri IL-2 simplifies the transition from research to process development for cell therapy manufacturing with minimized optimization time while supporting regulatory compliance.

Xuri products are supplied with a comprehensive documentation support package that follows USP <1043> requirements applicable to a supplier of ancillary material for cell, gene and tissue-engineered products to enable a full assessment and documentation of the production processes. This contributes significantly to facilitating risk assessment and validation in cell therapy manufacturing.

For more information, visit https://promo.gelifesciences.com/GL/XURI/expansion.html.

Read more:
GE Healthcare Launches Xuri IL-2 Growth Factor For The Reliable Activation And Expansion Of T-lymphocytes

Comments are closed.